{"id":"W2947529777","doi":"10.1200/jco.2019.37.15_suppl.tps5609","title":"NRG GY012: A randomized phase II study comparing single-agent olaparib, single agent cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent or metastatic endometrial cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Olaparib; Medicine; PARP inhibitor; Internal medicine; Oncology; Ovarian cancer; Clinical endpoint; Endometrial cancer; Randomized controlled trial; Pharmacology; Cancer; Poly ADP ribose polymerase; Biology; Polymerase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002924203,0.002401368,0.00302442,0.0006589247,0.0004493379,0.001036028,0.001555131,0.002383366,0.01192928],"category_scores_gemma":[0.002284697,0.001053152,0.002444781,0.000565925,0.001526927,0.001248898,0.0005493066,0.003212672,0.002299757],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001088938,"about_ca_system_score_gemma":0.001919622,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001094011,"about_ca_topic_score_gemma":0.003516504,"domain_scores_codex":[0.9991205,0.0005353792,0.00004289969,0.0001459153,0.00006123655,0.00009410577],"domain_scores_gemma":[0.9990243,0.0002519652,0.0002085879,0.00008834587,0.00005869729,0.0003681166],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9675565,0.01182356,0.0006554182,0.0005921789,0.0006054966,0.00005635972,0.00005626852,0.000309396,0.004313522,0.0001398253,0.001069968,0.0128213],"study_design_scores_gemma":[0.9162253,0.08200549,0.0006386676,0.00001800607,0.0001709349,0.00003553636,0.0000165855,0.0001710975,0.0001622066,0.00009449667,0.0004501205,0.00001157247],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.965381,0.004528569,0.001331111,0.002180749,0.001193272,0.01796544,0.003110868,0.0003676923,0.003941234],"genre_scores_gemma":[0.9576947,0.003566407,0.004878804,0.003739593,0.0006226322,0.01778735,0.003398499,0.00006846723,0.008243447],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01192928,"threshold_uncertainty_score":0.0399074,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2165671671857001,"score_gpt":0.4681063172353258,"score_spread":0.2515391500496257,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}